Shengli Li received his Ph.D. in Medical Systems Biology from Fudan University in 2018 and Postdoctoral training from the University of Texas Health Science center at Houston during 2018-2020. He is a Principal Investigator with the Shanghai General Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Shengli is a computational biologist with expertise in human cancer genetics. His research focuses on integrative utilization of cutting-edge computational biology algorithms and molecular experimental technologies to reveal systematical changes and functional factors in human cancer progression, cancer microenvironment and response to anti-cancer treatment.
Research interests
Our laboratory is committed to addressing pivotal questions in the field of human cancer biology through the application of state-of-the-art bioinformatics and genomics technologies. Specifically, we specialize in the integration of computational biology algorithms with molecular experimental techniques to elucidate the systematic changes and functional elements associated with cancer progression, the tumor microenvironment, and the response to anticancer therapies. Our research endeavors are directed towards advancing the frontiers of immunotherapy and precision medicine.
1. Cancer multi-omics
We employ bioinformatics approaches to dissect multi-omics cancer data, thereby elucidating cancer subtypes, driver genes, and the genetic underpinnings of various pathogenic mechanisms. This includes the identification of gene fusions, allelic alterations, and cancer-specific isoforms. Our research endeavors to uncover potential biomarkers and therapeutic targets for the diagnosis and treatment of cancer.
2. Carcinogenesis
Our research delves into the complex molecular mechanisms underlying the progression of carcinogenesis, employing an integrative approach. This approach encompasses the synthesis omics data (including both bulk and single-cell analyses) alongside molecular biology techniques and carcinogenesis animal models. Our primary focus encompasses colorectal, hepatic, and pancreatic cancers, though our scope is not confined to these areas.
3. Translational regulation
Our research focuses on examining the aberrant translational regulations and their corresponding products within the context of cancer, with a particular emphasis on noncanonical translational events originating from noncoding genomic regions.
4. Long-read sequencing
We are developing sophisticated computational methods aimed at enhancing the analysis of long-read RNA sequencing (lrRNA-seq) data, thereby facilitating a more comprehensive understanding of transcriptomic complexity and isoform diversity.